Journal
PERSONALIZED MEDICINE
Volume 18, Issue 5, Pages 491-499Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pme-2021-0024
Keywords
biomarker; esophageal cancer; gastric cancer; miR-101; target
Categories
Ask authors/readers for more resources
miR-101 is downregulated in various types of cancer, particularly playing a significant role in esophageal and gastric cancer, potentially serving as a promising new diagnostic and therapeutic target. It may also act as a significant predictive biomarker in esophagogastric cancer.
miR-101 is downregulated in various types of cancer, leading to the notion that miR-101 acts as a suppressor in cancer cell progression. The comprehensive mechanisms underlying the effects of miR-101 and the exact role of miR-101 dysregulations in esophagogastric tumors have not been fully elucidated. This review aims to summarize all current knowledge on the association between miR-101 expression and esophagogastric malignancies and to clarify the pathogenetic pathways and the possible prognostic and therapeutic role of miR-101 in those cancer types. miR-101 seems to play crucial role in esophageal and gastric cancer biology and tumorigenesis. It could also be a promising novel diagnostic and therapeutic target, as well as it may serve as a significant predictive biomarker in esophagogastric cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available